Orthopnea & Paroxysmal Nocturnal Dyspnea (PND) — Mechanisms

The Shared Pathophysiologic Cascade

Orthopnea

1. When the patient lies flat, gravity no longer pools blood in the lower extremities and splanchnic bed.
2. Venous return increases from the extremities and splanchnic circulation to the central (thoracic) circulation.
3. This raises ventricular preload, which a failing left ventricle cannot handle.
4. Pulmonary venous and pulmonary capillary hydrostatic pressures rise acutely.
5. Fluid shifts into the interstitium → reduced lung compliance → increased work of breathing.

Paroxysmal Nocturnal Dyspnea (PND)

Key Differences at a Glance

Why PND is Worse Than Orthopnea

Case Presentation: RHD with Severe MS + Severe PAH

Anticipated Professor Q&A

🔬 CATEGORY 1 — Etiology & Pathogenesis of RHD

The mechanism of valve damage in RHD is thought to be an autoimmune response to Group A Streptococcus (GAS) moieties that molecularly mimic valve antigens, involving both humoral and cellular immune mechanisms. Repeated untreated GAS pharyngeal infections accelerate progression. Carditis typically occurs in the second decade; significant MS develops 2 decades later. The mitral valve is the most commonly involved valve in RHD.

Classic RHD/MS has a female preponderance even though ARF affects both sexes equally — the reason is not fully understood but may relate to hormonal and immune differences affecting the autoimmune response.

• Leaflet thickening and fibrosis
• Commissural fusion — the dominant mechanism reducing valve area
• Chordal fusion and shortening (subvalvular disease)
• Calcification in advanced disease
• "Fish-mouth" or "buttonhole" valve appearance

❤️ CATEGORY 2 — Pathophysiology of MS

An increase in heart rate shortens diastole disproportionately more than systole, reducing the time available for blood to flow across the stenotic mitral orifice. At any given cardiac output, tachycardia (including AF with rapid ventricular response) augments the transvalvular pressure gradient and further elevates LA pressure. This is why events that cause tachycardia (fever, exercise, pregnancy, AF) precipitate acute decompensation in MS.

In isolated MS, LV diastolic pressure and EF are normal — the problem is upstream (LA, pulmonary circulation). However, in some patients with advanced RHD, the LV can be involved by the rheumatic process itself or compressed by the enlarged LA, leading to LV dysfunction.

In severe MS (MVA 1–1.5 cm²), CO is normal or near-normal at rest but rises subnormally during exertion. In very severe MS (MVA <1 cm²) with markedly elevated PVR, CO is subnormal at rest and may fail to rise — or even decline — during activity.

🫁 CATEGORY 3 — Pulmonary Hypertension in MS

There are four mechanisms (Harrison's):

1. Passive — backward transmission of elevated LA pressure (pulmonary venous HTN)
2. Reactive ("second stenosis") — pulmonary arteriolar vasoconstriction triggered by LA/pulmonary venous hypertension; initially reversible
3. Interstitial edema — in walls of small pulmonary vessels
4. Organic/obliterative — end-stage irreversible structural changes in the pulmonary vascular bed (intimal fibrosis, medial hypertrophy)

Reactive PAH is the vasoconstriction/remodeling of pulmonary arterioles in response to chronically elevated pulmonary venous pressure. It is called the "second stenosis" because it creates an additional fixed resistance in series with the mitral valve obstruction. It is initially reversible with relief of the mitral obstruction (BMV/surgery), but becomes irreversible at end stage when organic obliterative changes predominate.

Severe PAH → RV pressure overload → RV enlargement and hypertrophy → RV failure → secondary tricuspid regurgitation (TR) and pulmonary regurgitation (PR) → right-sided heart failure with JVD, hepatomegaly, ascites, peripheral edema.

Pulmonary artery systolic pressure (PASP) > 70 mmHg on echo (or mean PAP > 40 mmHg on catheterization). The European definition of PAH: mean PAP ≥ 25 mmHg at rest (updated 2022 definition: mean PAP > 20 mmHg).

🩺 CATEGORY 4 — Clinical Features & Auscultation

• Dyspnea on exertion → orthopnea → PND (as MS worsens)
• Hemoptysis — from rupture of pulmonary-bronchial venous connections due to pulmonary venous HTN
• Palpitations (AF)
• Systemic embolism (stroke)
• Features of right heart failure in severe PAH: edema, ascites, RHC pain

• Loud S1 (due to delayed, forceful mitral valve closure — mitral leaflets still open at end diastole)
• Opening snap (OS) — due to sudden tensing of mitral leaflets after valve "snaps" open
• A2-OS interval — shorter interval = more severe MS (elevated LA pressure causes earlier valve opening)
• Low-pitched mid-diastolic rumble with pre-systolic accentuation (if in sinus rhythm) at the apex, best heard in left lateral decubitus
• Loud P2 in PAH
• Graham-Steell murmur — early diastolic murmur at left sternal edge due to pulmonary regurgitation from PAH

S1 becomes soft when the mitral valve is heavily calcified (restricted mobility) or when the gradient is very low (very advanced MS with low flow).

Bilateral bluish-red discoloration of the cheeks due to low cardiac output and peripheral vasodilation from chronic MS. A classic but uncommon physical finding.

📊 CATEGORY 5 — Investigations

• P-mitrale — broad, notched P wave in lead II (>0.12 sec); biphasic P in V1 → LA enlargement
• RVH — right axis deviation, tall R in V1, deep S in V5-V6
• AF — absent P waves, irregularly irregular rhythm (very common in MS)

• Enlarged LA — double-density sign, elevation of left main bronchus, splaying of the carina
• Pulmonary venous HTN — upper lobe blood diversion, Kerley B lines
• Interstitial edema → alveolar edema (in decompensation)
• Hemosiderosis — fine nodular pattern (longstanding severe MS)
• RV enlargement — filling of retrosternal space on lateral view
• Enlarged MPA — convex left heart border at level of pulmonary artery segment

• Diastolic doming of the anterior mitral leaflet ("hockey stick" appearance)
• Commissural fusion
• MVA by planimetry < 1.5 cm²
• Pressure half-time (PHT) ≥ 220 ms → MVA = 220/PHT
• Mean transmitral gradient > 10 mmHg (severe)
• Elevated PASP
• LA enlargement, LA thrombus assessment

The Wilkins (echocardiographic) score assesses 4 parameters, each scored 0–4:

1. Leaflet mobility (restricted = higher score)
2. Leaflet thickening
3. Calcification
4. Subvalvular apparatus deformity

Total score 0–16.

• Score ≤ 8 → favorable morphology → PTMC/BMV likely successful (>90%)
• Score 9–11 → intermediate; consider BMV at experienced centers
• Score > 11 → suboptimal morphology → surgery preferred

💊 CATEGORY 6 — Management

• LA thrombus (absolute — must anticoagulate for 2–3 months, recheck TEE)
• MR ≥ 2+ (PTMC may worsen it)
• Wilkins score > 11 (relative)
• Severe bicommissural calcification
• Severe subvalvular disease

• Severe PAH is actually an indication for PTMC (even in asymptomatic patients, if PASP > 50 mmHg)
• After successful PTMC, reactive PAH often reverses over months
• Fixed/obliterative PAH does not reverse — presence of very high PVR (>10 Wood units) increases surgical risk significantly
• Severe PAH with RV failure makes the patient a higher surgical risk

• Warfarin (vitamin K antagonist) — target INR 2.5–3.5
• NOT direct oral anticoagulants (DOACs) — DOACs are contraindicated in rheumatic MS with AF (this distinction is critical — the RE-ALIGN trial showed dabigatran was inferior in mechanical valves; ESC/ACC guidelines explicitly state warfarin only for rheumatic MS)
• Anticoagulation is indicated regardless of CHADS₂-VASc score in MS + AF
• Consider anticoagulation in sinus rhythm if: dense spontaneous echo contrast in LA or LA dilation (European guidelines)

Rate control is a cornerstone of medical management:

• Beta-blockers (metoprolol, bisoprolol) or ivabradine — slow heart rate, prolong diastolic filling time, reduce transmitral gradient
• Digoxin — useful for rate control in AF
• Diuretics for pulmonary congestion There is no drug that treats the mechanical obstruction; medical therapy is symptomatic only.

⚡ CATEGORY 7 — Complications

MS + AF is a particularly high-risk combination:

• Reduced LA appendage emptying velocity
• LA stasis → thrombus formation (especially in the LA appendage)
• Risk of embolism is 17–18× higher in MS+AF vs controls
• Even transient AF episodes increase risk significantly
• MS patients can have LA thrombus even in sinus rhythm

Rupture of pulmonary-bronchial venous connections secondary to acute rise in pulmonary venous pressure. Most common in patients with elevated LA pressure without markedly elevated PVR (because if PVR is high, it acts as a "buffer" reducing pulmonary venous pressure swings). Rarely fatal but recurrent.

Dismal:

• Mortality 8–13% per year in the first 5 years
• Only 15% of NYHA Class IV patients survive 5 years without intervention
• 60% of NYHA Class III survive 5 years without intervention

🤰 BONUS CATEGORY 8 — Special Situations

• Pregnancy increases blood volume and heart rate → elevated LA pressure → acute pulmonary edema
• Severe PAH is an absolute contraindication to pregnancy (maternal mortality up to 50%)
• Severe MS (MVA ≤1.5 cm²) with symptoms or PAH should be treated before conception, preferably with PTMC
• Warfarin is teratogenic (especially 6–12 weeks) — requires careful anticoagulation strategy

Major criteria (JONES): Joints (migratory polyarthritis), O (rheumatic carditis), Nodules (subcutaneous), Erythema marginatum, Sydenham's chorea Minor criteria: Fever, elevated ESR/CRP, prolonged PR interval Plus evidence of prior GAS infection (elevated ASO titer, positive throat culture)

🎯 Top 5 "Must-Know" Questions Professors Always Ask

1. Mechanisms of PAH in MS (Q8) — the 4 mechanisms, especially reactive/"second stenosis"
2. Wilkins Score (Q19) — all 4 parameters, cutoffs for PTMC vs surgery
3. Auscultatory signs (Q13) — why S1 is loud, A2-OS interval correlating with severity
4. Indications for PTMC vs surgery (Q20) — Class I and IIa indications especially
5. Warfarin NOT DOACs in MS+AF (Q23) — professors specifically test this distinction

🔑 High-Yield Facts for PAH in Your Case

• Severe PAH (PASP >50 mmHg) is itself an indication for PTMC even in asymptomatic patients
• Reactive PAH reverses after successful PTMC; obliterative PAH does not
• RV failure from PAH significantly increases surgical risk
• The 4-mechanism cascade (passive → reactive → interstitial edema → obliterative) is the signature pathophysiology question for Group 2 PAH due to MS